Rivaroxaban versus warfarin in postoperative atrial fibrillation: Cost-effectiveness analysis in a single-center, randomized, and prospective trialCentral MessagePerspective von Marcel de Paula Pereira, MD, Eduardo Gomes Lima, MD, PhD, Fabio Grunspun Pitta, MD, Luís Henrique Wolff Gowdak, MD, PhD, Bruno Mahler Mioto, MD, PhD, Leticia Neves Solon Carvalho, MD, Francisco Carlos da Costa Darrieux, MD, PhD, Omar Asdrubal Vilca Mejia, MD, PhD, Fabio Biscegli Jatene, MD, PhD, Carlos Vicente Serrano, Jr, MD, PhD

Volltext